Table 2.

Effects of COX inhibitors on C5aAP-induced VP changes

Vascular leakage (μl blood/g skin)
Without C5aAPTreated with C5aAP
25% PG (control)38.8 ± 4.660.7 ± 12.4a
Indomethacin (5 mg/kg)35.1 ± 2.745.9 ± 2.7b
NS-398 (0.1 mg/kg)45.2 ± 4.849.2 ± 13.6
NS-398 (5 mg/kg)ND44.3 ± 2.1b
  • Note: Mice were treated i.p. with indomethacin or NS-398 35 min before 125I-IgG administration. Each value represents the mean ± SD of four to six mice.

  • a Significantly different from basal VP (P < 0.05).

  • b Significantly different from controls treated with C5aAP (P < 0.05).